The Swiss pharmaceutical group NOVARTIS finalised the sale of its fungicides FLINT to its German competitor BAYER for CHF 1.33 billion. BAYER valued at some EUR 300 million the potential annual turnover of the FLINT fungicides. Furthermore, NOVARTIS will invest USD 43 million to take a stake in the capital of GENEVA POTEOMICS, specialised in proteomics (decrypting proteins).